419 related articles for article (PubMed ID: 32019575)
1. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
2. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Lee M; Chung WB; Lee JE; Park CS; Park WC; Song BJ; Youn HJ
Cancer Med; 2021 Jun; 10(12):3964-3973. PubMed ID: 33998163
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
6. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
7. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
Huang S; Zhao Q; Yang ZG; Diao KY; He Y; Shi K; Shen MT; Fu H; Guo YK
Heart Fail Rev; 2019 May; 24(3):325-333. PubMed ID: 30523513
[TBL] [Abstract][Full Text] [Related]
8. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Avila MS; Ayub-Ferreira SM; de Barros Wanderley MR; das Dores Cruz F; Gonçalves Brandão SM; Rigaud VOC; Higuchi-Dos-Santos MH; Hajjar LA; Kalil Filho R; Hoff PM; Sahade M; Ferrari MSM; de Paula Costa RL; Mano MS; Bittencourt Viana Cruz CB; Abduch MC; Lofrano Alves MS; Guimaraes GV; Issa VS; Bittencourt MS; Bocchi EA
J Am Coll Cardiol; 2018 May; 71(20):2281-2290. PubMed ID: 29540327
[TBL] [Abstract][Full Text] [Related]
9. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Abuosa AM; Elshiekh AH; Qureshi K; Abrar MB; Kholeif MA; Kinsara AJ; Andejani A; Ahmed AH; Cleland JGF
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S96-S100. PubMed ID: 30595329
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
Tashakori Beheshti A; Mostafavi Toroghi H; Hosseini G; Zarifian A; Homaei Shandiz F; Fazlinezhad A
Cardiology; 2016; 134(1):47-53. PubMed ID: 26866364
[TBL] [Abstract][Full Text] [Related]
12. Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.
Zhan T; Daniyal M; Li J; Mao Y
Herz; 2020 Dec; 45(Suppl 1):1-14. PubMed ID: 30656389
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Guglin M; Krischer J; Tamura R; Fink A; Bello-Matricaria L; McCaskill-Stevens W; Munster PN
J Am Coll Cardiol; 2019 Jun; 73(22):2859-2868. PubMed ID: 31171092
[TBL] [Abstract][Full Text] [Related]
14. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
Cannata F; Stefanini G; Carlo-Stella C; Chiarito M; Figliozzi S; Novelli L; Lisi C; Bombace S; Panico C; Cosco F; Corrado F; Masci G; Mazza R; Ricci F; Monti L; Ferrante G; Santoro A; Francone M; da Costa BR; Jüni P; Condorelli G
J Cardiovasc Med (Hagerstown); 2023 Jul; 24(7):469-474. PubMed ID: 37285278
[TBL] [Abstract][Full Text] [Related]
17. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
18. Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy.
Shah P; Garris R; Abboud R; Vasudev R; Patel H; Doshi R; Shamoon F; Bikkina M
Am J Cardiol; 2019 Sep; 124(5):789-794. PubMed ID: 31307662
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Kheiri B; Abdalla A; Osman M; Haykal T; Chahine A; Ahmed S; Osman K; Hassan M; Bachuwa G; Bhatt DL
Am J Cardiol; 2018 Dec; 122(11):1959-1964. PubMed ID: 30292333
[TBL] [Abstract][Full Text] [Related]
20. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
